Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ORMD-0801
- Development stage
- Phase 3
- Lead developer
- Oramed Pharmaceuticals
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Administration
- Oral
01
Overview
ORMD-0801 is an oral insulin formulation developed by Oramed Pharmaceuticals. It consists of insulin packaged in an enteric-coated capsule with EDTA and bile salts as penetration enhancers. The capsule facilitates passage through the stomach into the small intestine, where the enhancers promote drug permeability by opening tight junctions. This oral delivery system aims to create a new paradigm in diabetes treatment by enabling earlier intervention, potentially slowing disease progression and delaying complications.
- Brand names
- Tianoulin
- Other names
- insulin in dextran matrixoral insulin (Oramed)ORMD0801ORMD-0801ORMD 0801
02
Targets
INSR (Insulin receptor)
Beyond the preview
Go deeper on ORMD-0801.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ORMD-0801.